This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Karsten Putzbach: Innovator in Modified Release Formulations
Introduction
Karsten Putzbach is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of drug formulations. His work focuses on innovative solutions for treating complex medical conditions.
Latest Patents
Karsten Putzbach holds a patent for a modified release formulation for (-)-(3AR,4S,7AR)-4-hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester. This patent, which is particularly relevant for drug products aimed at treating patients with Parkinson's disease and L-dopa induced dyskinesia, showcases his expertise in creating effective pharmaceutical solutions. The patent details processes for making drug products that utilize the substance (−)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056).
Career Highlights
Karsten Putzbach is associated with Novartis AG, a leading global healthcare company. His role at Novartis has allowed him to work on groundbreaking projects that aim to improve patient outcomes through innovative drug formulations. His dedication to research and development has positioned him as a key player in the pharmaceutical industry.
Collaborations
Throughout his career, Karsten has collaborated with esteemed colleagues such as Mike Ufer and Klaus-Peter Moll. These collaborations have fostered an environment of innovation and have contributed to the advancement of pharmaceutical research.
Conclusion
Karsten Putzbach's contributions to the field of modified release formulations highlight his commitment to improving healthcare solutions. His innovative work continues to impact the treatment of Parkinson's disease, showcasing the importance of research and development in the pharmaceutical industry.